In­Car­da grabs a $42M round to back PoC study for their in­haled car­dio drug

San Fran­cis­co-based In­Car­da Ther­a­peu­tics is tak­ing a big step for­ward to­day, un­veil­ing a $42 mil­lion B round af­ter get­ting the com­pa­ny launched on a shoe­string …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER